In 2019, the immune checkpoint inhibitor pembrolizumab was approved by the Food and Drug Administration (FDA) as a second-line therapy to treat patients with locally advanced or metastatic ESCC whose tumors are positively expressing PD-L1 (Combined Positive Score [CPS] ≥10) (22). Here, CD274 is linked to esophageal squamous cell carcinoma.